Áñ°Üã±â ȸ¿ø°¡ÀÔ ¿µ¹®»çÀÌÆ® my½ºÅ©·¦
BT½ºÆä¼ÈŸÀÌÆ²
Àü¹®°¡¸®Æ÷Æ®
¼¼°è´ÂÁö±Ý
¹ß°£¼­View
Áֿ伺°ú
À̽´&ƯÁý
TheÀÎÅͺä
BTÀü¹®°¡Á´ãȸ
»ý¸í°øÇÐÁ¤Ã¥¿¬±¸Æ÷·³
ÇØ¿ÜBT³×Æ®¿öÅ©
ÇØ¿ÜBT³×Æ®¿öÅ© HOMEBT½ºÆä¼ÈÇØ¿ÜBT³×Æ®¿öÅ©ÀÚ·á
 
³×Æ®¿öÅ©ÀÚ·á Æ÷Åä¸ðÀ½  
ÆäÀ̽ººÏ Æ®À§ÅÍ ¹ÌÅõµ¥ÀÌ  ¸¶À̽ºÅ©·¦ Àμâ
KASBP(Korean American Society in Biotech and Pharmaceuticals)
ÀúÀÚ/Ãâó ÇÑ¿ëÇØ/(KASBPȸÀå, BMS) µî·ÏÀÏ 2011-10-19 Á¶È¸ 11682
³»¿ë¹Ù·Î°¡±â http://www.kasbp.org

 Àç¹Ì BTÇÑÀΰúÇÐÀÚ ³×Æ®¿öÅ© ¼Ò°³

 

KASBP
(Korean American Society in Biotech and Pharmaceuticals)

 


ÇÑ¿ëÇØ (KASBPȸÀå, BMS)

¡à °³¿ä


KASBP (Korean American Society in Biotech and Pharmaceuticals, Àç¹ÌÇÑÀÎ Á¦¾àÀÎÇùȸ, http://www.kasbp.org/)´Â ´ÙÀ½°ú °°Àº ¼¼ °¡ÁöÀÇ ¸ñÇ¥¸¦ ÀÌ·ç±â À§ÇØ 2001³â 5¿ù¿¡ ¼³¸³µÈ ºñ¿µ¸® ´ÜüÀÌ´Ù.


1. ½Å¾à°³¹ßÀ» Æ÷ÇÔÇÏ´Â »ý¸í°úÇÐ ºÐ¾ßÀÇ ÁÖ¿ä À̽´¿¡ ´ëÇÑ ÇмúÁ¤º¸ ±³·ù¿Í ȸ¿ø°£ÀÇ ³×Æ®¿öÅ©¸¦ °­È­ÇÑ´Ù.


2. Çѱ¹ÀÇ ¹ÙÀÌ¿ÀÅ×Å©, Á¦¾àȸ»ç ¹× Á¤ºÎÃ⿬ ¿¬±¸±â°üµé°ú ±ä¹ÐÇÑ Çù·ÂÀ» ÅëÇØ »óÈ£ °ü½É»ç¸¦ °øÀ¯Çϸ鼭 Çѱ¹ÀÇ ½Å¾à¿¬±¸°³¹ß°ú °³¹ß±â¼úÀÇ »ó¾÷È­°¡ Ȱ¼ºÈ­µÉ ¼ö ÀÖµµ·Ï Áö¿øÇÑ´Ù.


3. ÀáÀç·Â ÀÖ´Â ÀþÀº ÇÑÀÎ ¿¬±¸ÀÚµéÀ» ¹ß±¼ÇÏ¿© Çѱ¹ »ý¸í°úÇаú Á¦¾à»ê¾÷ÀÇ ¹Ì·¡¸¦ ¸¸µé¾î °¥ Àü¹®°¡µé·Î À°¼ºÇÑ´Ù.


Áö¿ªÀûÀ¸·Î´Â ¹Ì±¹ Á¦¾à»ê¾÷ÀÇ Áß½ÉÁöÀÎ ´ºÀúÁö¸¦ Áß½ÉÀ¸·Î Ȱµ¿Çϰí ÀÖÀ¸¸ç, Çʶóµ¨ÇÇ¾Æ¿Í º¸½ºÅÏ¿¡ °¢°¢ ÁöºÎ¸¦ µÎ°í ÀÖ´Ù.


2001³âµµ ºÎÅÍ Á¦1´ë ȸÀå ¹èÁø°Ç ¹Ú»ç (Shering-Plough, Çö Áß¿ÜÁ§¾à)À» ½ÃÀÛÀ¸·Î, ¹Ú¿µÈ¯ ¹Ú»ç (2´ë; Merck, Çö ´ë¿õÁ¦¾à), ¹®¿µÃá ¹Ú»ç(3, 6´ë; PTC Therapeutics), ±èÈ«¿ë ¹Ú»ç(4´ë; Norvatis), ÀÌÇÐ¸í ¹Ú»ç(5´ë; Medarex, ÇöShionogi), ÀÓ¼ºÅà ¹Ú»ç(7´ë; Sanofi-Aventis) ÀüÀÓ È¸ÀåµéÀÌ ÀçÀÓÇÑ ¹Ù ÀÖÀ¸¸ç ÇöÀç´Â Á¦8´ë ȸÀå ÇÑ¿ëÇØ ¹Ú»ç (Bristol-Myers Squibb)¸¦ ±¸½ÉÀ¸·Î 25¸íÀÇ ÀÓ¿øµéÀÌ È°µ¿Çϰí ÀÖ´Ù.


KASBPÀÇ È¸¿øÀ¸·Î´Â ¹Ì±¹ Àü¿ª ¹× Çѱ¹¿¡ ¼ÒÀçÇÏ´Â 122°³ÀÇ ±â¾÷ Á¾»çÀÚµé (BMS, Novartis, GSK, Merck, Sanofi, J&J, Pfizer, etc)°ú 59°³ÀÇ ¾ÆÄ«µ¥¹Ì¾Æ¿¡ ¼Ò¼ÓµÈ ±³¼ö, ¿¬±¸¿ø ¹× ´ëÇпø»ý µî ÇÐ°è °ü°èÀÚµé°ú ¹Ì±¹ ½ÄǰÀǾàǰ¾ÈÀüû(FDA), ±¹¸³º¸°Ç¿ø(NIH) µî Á¤ºÎ±â°ü ±Ù¹«ÀÚµé µî ÃÑ486 ¸íÀÇ È¸¿øµéÀÌ Âü¿©Çϰí ÀÖ´Ù (2011³â 9¿ù 27ÀÏ ÇöÀç).


Çмú Ȱµ¿ À̿ܿ¡µµ, ȸ¿øµéÀÇ ±¸ÀÎ ¹× ±¸Á÷À» Àû±ØÀûÀ¸·Î ÈÄ¿øÇϰí, Àç¹Ì°úÇбâ¼úÀÚÀÚÇùȸ ´ºÀúÁö ÁöºÎ (KSEA-NJ)¿Í ÇÔ²² û¼Ò³âµéÀ» ´ë»óÀ¸·Î ÇÏ´Â ¼öÇаæ½Ã´ëȸ¸¦ °³ÃÖÇϰí ÀÖÀ¸¸ç, ȸ¿øµé°£ÀÇ Ä£¸ñÀ» µµ¸ðÇϱâ À§ÇØ º¼¸µ´ëȸ, °ñÇÁ´ëȸ, ¾ßÀ¯È¸, ¼Û³âȸ, ½Å³âȸ µîÀÇ Ä£¸ñ ¸ðÀÓµµ Á¤±âÀûÀ¸·Î °³ÃÖÇϰí ÀÖ´Ù.


KASBP´Â Çѱ¹Á¤ºÎ·ÎºÎÅÍ Áö³­ 10³â°£ÀÇ È°µ¿¿¡ ´ëÇÑ °ø·Î¸¦ ÀÎÁ¤¹Þ¾Æ 2011³â 3¿ù 31ÀÏ ¹Ì±¹ ´º¿å¿¡¼­ ¿­¸° <Çѱ¹ÀÇ·áÇö´ëÈ­ 50Áֳ⠱â³äÇà»ç>¿¡¼­ Áø¼öÈñ º¸°Çº¹ÁöºÎ Àå°üÀ¸·ÎºÎÅÍ °ø·Î»ó¸¦ ¹ÞÀº ¹Ù ÀÖ´Ù.


KASBP¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸´Â ȨÆäÀÌÁö (kasbp.org)¿¡¼­ ãÀ» ¼ö ÀÖ´Ù.

 


¡à ÁÖº¯ÀÇ ÁÖ¿ä ¿¬±¸È¯°æ ¼Ò°³

 

±â°ü

±â´É

¿¬±¸ºÐ¾ß

Bristol-Myers Squibb (BMS)

½Å¾à °³¹ß

°¢Á¾ ¾Ï, ´ç´¢º´, CÇü°£¿°, Ä¡¸Å, ·ù¸¶Æ¼Áò, µ¿¸Æ°æÈ­Áõ Ä¡·áÁ¦ µî °³¹ß

Merck

½Å¾à °³¹ß

¾Ë·¯Áö, ºÒ¸éÁõ, CÇü°£¿°, ´ç´¢º´, ³ì³»Àå, °¢Á¾¾Ï, °ñ´Ù°øÁõ Ä¡·áÁ¦ °³¹ß

Sanofi

½Å¾à°³¹ß

¼øÈ¯±â Áúȯ, ´ë»ç¼º Áúȯ, Á¾¾ç, ¾È°ú Áúȯ, Ç÷ÇàÀå¾Ö Ä¡·áÁ¦ °³¹ß

Norvatis

½Å¾à°³¹ß

¿ì¿ïÁõ, CÇü °£¿°, ´ç´¢º´, °ñ´Ù°øÁõ, ½ÉºÎÀüÁõ, °üÀý¿°, °íÇ÷¾Ï, ¾Ë·¯Áö, õ½Ä Ä¡·áÁ¦ °³¹ß

Johnson & Johnson

½Å¾à°³¹ß

´ç´¢º´, ·ù¸¶Æ¼Áò, CÇü °£¿°, Ä¡¸Å, ½ÅºÎÀüÁõ, ³úÀÏÇ÷ Ä¡·áÁ¦ °³¹ß

GlaxoSmithKline (GSK)

½Å¾à°³¹ß

Ä¡¸Å, °£Áú, ´ë»ç¼ºÁúȯ, ·ù¸¶Æ¼Áò, °ñ´Ù°øÁõ, ½ÉºÎÀüÁõ, ´ç´¢º´, µ¿¸Å°æÈ­, CÇü°£¿°, ÀÎÇ÷翣ÀÚ, õ½Ä Ä¡·áÁ¦ °³¹ß

 

 

¡à Ȱµ¿ ¹× Çà»ç


KASBP´Â ¸Å³â º½°ú °¡À»¿¡ °¢°¢ Á¤±â ½ÉÆ÷Áö¾öÀ» °³ÃÖÇÏ¿© ½Å¾à°³¹ß ºÐ¾ßÀÇ »õ·Î¿î À̽´µé°ú Æ®·»µå¸¦ ÁýÁßÀûÀ¸·Î Á¶¸ÁÇϰí ÀÖÀ¸¸ç, À̸¦ À§ÇØ ¹Ì±¹ÀÇ ±â¾÷, ´ëÇÐ, ¿¬±¸¼Ò ¹× FDA µî¿¡¼­ Ȱµ¿Çϰí ÀÖ´Â °ü·Ã Àü¹®°¡µé·Î ±¸¼ºµÈ Åä·Ðȸ¸¦ °³ÃÖÇÏ¿© »õ·Î¿î Á¤º¸µéÀ» °øÀ¯Çϰí ÀÖ´Ù.

 


2010 °¡À» ½ÉÆ÷Áö¿ò

 


2011 º½ ½ÉÆ÷Áö¿ò

 


FDA ½É»ç°üµé°úÀÇ Åä·Ðȸ

 


ÀåÇÐ±Ý ½Ã»ó½Ä


¡à ÇâÈÄ ¹æÇâ ¹× ¸ñÇ¥


KASBP´Â Çѱ¹ Á¦¾à»ê¾÷ÀÇ ¼ºÀå°ú ¹ßÀüÀ» À§ÇØ ½Å¾à°³¹ßÀ» Æ÷ÇÔÇÏ´Â »ý¸í°úÇÐ ºÐ¾ßÀÇ ÁÖ¿ä À̽´¿¡ ´ëÇÑ ÇмúÁ¤º¸ ±³·ù¿Í Çù·ÂÀ» ¸ð»öÇϰí ÀÖ´Ù.


ƯÈ÷ ÃÖ±Ù¿¡´Â ½Å¾à°³¹ß Ȱµ¿À» °­È­Çϰí ÀÖ´Â ±¹³» Á¦¾àȸ»ç ¹× ¿¬±¸¼Òµé°ú ´Ù¾çÇÑ ÇüÅÂÀÇ Çù·Â°ú Çù¾÷À» ÅëÇØ ¼öÁØ ³ôÀº Á¤º¸¸¦ ±³·ùÇϸ鼭 Çѱ¹³»ÀÇ ½Å¾à ¿¬±¸È°µ¿À» ½ÇÁúÀûÀ¸·Î Áö¿øÇϴ Ȱµ¿À» Ȱ¹ßÈ÷ ÆîÃijª°¥ °èȹÀÌ´Ù.


¿¹¸¦ µé¾î, ½Å¾à°³¹ß¿¡ ´ëÇÑ ½ÇÁúÀûÀÎ Á¤º¸ ±³·ù¸¦ ÃËÁøÇϰíÀÚFDA °°Àº Çã°¡±â°ü¿¡¼­ ÀÏÇÏ´Â ½É»ç°üµé°ú Çѱ¹Á¦¾à±â¾÷ÀÇ ¿¬±¸ÀÚµé°úÀÇ Á¢ÃË ±âȸ¸¦ ´Ã¸®´Â ÀÏ¿¡µµ ¿ªÁ¡À» µÑ ¿¹Á¤ÀÌ´Ù.

 

¡à KASBP ¿î¿µÁø ¸®½ºÆ®

 

¼º¸í

Á÷Ã¥

¼Ò¼Ó±â°ü

ÇÑ¿ëÇØ

President

BMS

ÀÓÇÑÁ¶

President Designated

Sanofi

ÃÖ³«Çö

1st Vice President

PTC Ther.

±èÀçÈÆ

2nd Vice President

Merck

̅˱

1st Executive Director

Lucas & Mercanti

±è¼º±Ç

2nd Executive Director

Merck

Ȳ¼º¿ì

Financial Director

PTC Ther.

·ùÁ¦ÇÊ

Audit

NAL Pharma

ÀÌÁ¤ÈÆ

Web Director

Merck

½ÅÇå¿ì

Public Relations Director

SK Bio-Pharm

±è¿µ¼±

General Director

VaxInnate

·ùÀºÁÖ

Marketing Director

Pfizer

Á¤Ã¶±Ù

1st Membership Director

Merck

°øÁ¾¶ô

2nd Membership Director

Merck

Á¶µµÇö

Corporate Director

KHIDI

ÀÌ Eliz

Legal Director

Lucas & Mercanti

ÃÖ Chris

Publication Director

Colgate-Palmolive

¼­³­ÁÖ

Science Director

Rutgers Univ

±è¼º³à

Program Director

BMS

¼º¹«Á¦

Boston ÁöºÎÀå

Novartis

Áø¿ëȯ

Philadelphia ÁöºÎÀå

GSK

¹®¿µÃá

Councilor

PTC Ther.

±èÈ«¿ë

Councilor

Novartis

ÀÌÇиí

Councilor

Shionogi USA

ÀÓ¼ºÅÃ

Councilor

Sanofi


 


 


÷ºÎÆÄÀÏ
  KASBP.pdf  (451008) bytes
ÀÌÀü±Û KOLIS(Korean LIfe Scientists in the bay area)
´ÙÀ½±Û BLSA(Baltimore Life Scientists Association)
ÆäÀ̽ººÏ Æ®À§ÅÍ ¹ÌÅõµ¥ÀÌ  ¸ñ·Ï
°ü·Ã±â»ç
[] KASBP(Korean American Society in Biotech and ... 2011-10-19
 
   
ÇÑ±Û ¿öµå
ÆÄ¿öÆ÷ÀÎÆ® ¾ÆÅ©·Î¹î